A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23.

¹ Biology, University of New Brunswick, Saint John, NB, Canada;
² Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada;
³ Hematology, Vancouver General Hospital, Vancouver, BC, Canada;
⁴ Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, NS, Canada;
⁵ Oncology, Princess Margaret Hospital, Toronto, ON, Canada;
⁶ Oncology, London Health Sciences Centre, London, ON, Canada;
⁷ Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada;
⁸ Centre for Individualized Medicine, Mayo Clinic Arizona, Scottsdale, AZ;
⁹ Laboratory Medicine, Saint John Regional Hospital, Saint John, NB, Canada;
¹⁰ Department of Internal Medicine, Queen's University, Kingston, ON, Canada;
¹¹ Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;
¹² Juravinski Hospital and Cancer Centre and McMaster University, Hamilton ON, Canada; and.
¹³ Biology, University of New Brunswick, Saint John, NB, Canada; Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB, Canada.

No abstract available

Publication types